News & Events

The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Impel Neuropharma Announces Publication of Narrative Review in The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment of Migraine

November 20, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that a narrative review of…

Impel NeuroPharma Announces Appointment of Diane Wilfong To Board of Directors

SEATTLE, October 17, 2019 — Impel NeuroPharma today announced that Diane Wilfong has been appointed to the Company’s board of directors. Diane brings 30 years of financial and operations experience in large, multinational companies, including most currently serving as Senior…

Impel NeuroPharma To Present Data From INP104 Clinical Program At The 19th Congress of the International Headache Society

SEATTLE, September 5, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that it will present…

Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine

SEATTLE, September 3, 2019 — Impel NeuroPharma today announced the last patient has been enrolled in “STOP-301” (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute…

Impel NeuroPharma to Present Data from INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society

SEATTLE, July 10, 2019 — Previously Reported STOP 101 Data, Including New Analysis Evaluating Cardiovascular Effects of Dihydroergotamine Mesylate (DHE) Delivered by Impel’s POD® Device, Support Bioavailability, Safety and Tolerability Profile of INP104 for Acute Migraine. Company’s Phase 3 Clinical…

Impel NeuroPharma Appoints John Leaman as Chief Financial Officer

SEATTLE, June 26, 2019 — Impel NeuroPharma today announced the appointment of John Leaman, M.D., as the Company’s Chief Financial Officer.

Impel NeuroPharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

SEATTLE, May 17, 2019 — Phase 1 Data Support Selection of Company’s Proprietary Formulation of Investigational Nasal Olanzapine, INP105, Currently Being Evaluated for Acute Agitation in Bipolar 1 and Schizophrenia

Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

SEATTLE, April 30, 2019 — Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019…

Impel NeuroPharma Appoints Jennifer L. Berman as Vice President of Marketing

SEATTLE, February 19, 2019 — Significant Leadership Experience in CNS Marketing to Help Impel Evolve into a Fully-Integrated R&D and Commercial Organization. Impel NeuroPharma today announced that Jennifer L. Berman has joined the Company as the Vice President of Marketing.

Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

SEATTLE, Jan. 6, 2019 /PRNewswire/ — Data Demonstrated Nasal Delivery of INP105 (POD-olanzapine) Achieved Peak Olanzapine Plasma Levels Twice as Fast as Intramuscular Injection, Ten-Times Faster than Orally-Disintegrating Tablets Study Showed a Safety and Tolerability Profile Consistent with Currently Marketed…